Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Mbah’s Drive to End Capital Flight in Health Tourism on Course

Emmanuel Ugwu-Nwogo in Umuahia Governor Peter Mbah’s drive to reverse medical tourism and halt the attendant capital flight remains on course, the Chief Executive Officer(CEO) of Enugu International Hospital (EIH),

Enugu International Hospital (EIH), a 300-bed facility almost ready for inauguration, is a manifestation of Governor Peter Mbah's ambition to curb medical tourism and capital flight, according to Professor Sam Agwu, the hospital's CEO. Agwu stated that the facility will make advanced medical services available in Enugu, which are currently sought by privileged Nigerians abroad.

He estimates that the hospital would reduce the capital outflow by 40 percent within the first year of operation by offering topnotch medical services and cutting-edge equipment. After stemming the flow of Nigerians going abroad for healthcare, EIH is poised to attract patients from outside Nigeria, including Europe and America, due to the cheaper and equal-quality medical care provided.

Prof. Agwu highlighted that EIH will have specialized sections for cancer care, cardiology, nephrology, and orthopaedic surgery. The hospital will also offer a cardiothoracic surgical team led by a UK-based surgeon, nuclear medicine capabilities with a PET scan, and neuroscience medicine. An array of advanced medical equipment, including CT scans, MRIs, and mammography machines, is already installed at the hospital.

Once inaugurated, EIH will provide the best medical care to its patients with dignity and compassion.

Written by urgent.news from This Day's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at thisdaylive.com →

More in Health & Medicine

Novo Nordisk FDA Setback Creates Opportunity for Korean CDMOs

Denmark’s Novo Nordisk, which has led the global pharmaceutical and biotech market on the back of explosive demand for the obesity treatments Wegovy and Ozempic, has run into an unexpected hurdle as…

  • FDA withholds approval for Novo Nordisk facilities due to quality-control violations.
  • Novo Nordisk's Bloomington facility received critical observations, including sterility failures.
  • Korean CDMOs like Celltrion and Samsung Biologics benefit from regulatory challenges.

Biosolution Signs Cartilife Supply Deal in China

Biosolution is accelerating its efforts to target the Chinese market, spearheaded by its autologous chondrocyte therapy ‘Cartilife’.Biosolution announced on August 13 that it signed a final…

  • Hospital can perform Cartilife therapy to 1,000 patients annually with GMP facilities.
  • Biosolution CEO sees partnership as turning point for local revenue generation in China.

More from Thursday 13 August →